Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 10/20 | 0.47 |
| ▸ | F13A1 | P00488 | 7/20 | 0.47 |
| ▸ | TGM1 | P22735 | 4/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3194967 | 0.83 | TGM2 (0.64) | ALDH1A1CYP2D6POLBTGM2F13A1 | |
| SCHEMBL15201008 | 0.83 | POLB (0.56) | ALDH1A1CYP2D6POLBCHRM1CHRM5 | |
| SCHEMBL17062363 | 0.81 | STS (0.47) | TGM2F13A1TGM1STS | |
| SCHEMBL30049771 | 0.73 | NAMPT (0.55) | POLBTGM2F13A1TGM1 | |
| SCHEMBL14055908 | 0.73 | NAMPT (0.54) | ALDH1A1CYP2D6POLBTGM2F13A1 | |
| SCHEMBL17670 | 0.73 | PKM (0.52) | ALDH1A1POLBPKM | |
| SCHEMBL18701970 | 0.72 | ALDH1A1 (0.61) | ALDH1A1CYP2D6POLBTGM2F13A1 | |
| SCHEMBL30050129 | 0.72 | POLB (0.50) | ALDH1A1CYP2D6POLBTGM2F13A1 | |
| SCHEMBL5697752 | 0.71 | ALDH1A1 (0.67) | ALDH1A1CYP2D6POLBCHRM1PKM | |
| SCHEMBL22650785 | 0.71 | POLB (0.44) | ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | ALDH1A1 3293/4885CYP2D6 1222/4885POLB 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.